Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Patent Office sides with Merck & Co on validity of Singulair patent

This article was originally published in Scrip

Executive Summary

A key patent held by Merck & Co will stand despite a challenge by an outside group that had raised new questions on its patentability. Merck said that the US Patent and Trademark Office has agreed with its arguments regarding the validity of patent No 5,565,473 covering the active ingredient of its top-selling asthma drug Singulair (montelukast sodium).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC006154

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel